Patents Assigned to The Rockefeller University
  • Publication number: 20170189431
    Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
    Type: Application
    Filed: September 26, 2016
    Publication date: July 6, 2017
    Applicant: The Rockefeller University
    Inventors: Sean BRADY, Hahk-Soo Kang
  • Patent number: 9657101
    Abstract: The present invention provides reagents, methods and systems for predicting the inhibitory activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A/I ratio), wherein the magnitude of said ratio is less than one (1).
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 23, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Rene G. Ott
  • Publication number: 20170130214
    Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.
    Type: Application
    Filed: June 26, 2015
    Publication date: May 11, 2017
    Applicant: The Rockefeller University
    Inventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
  • Patent number: 9642909
    Abstract: Disclosed herein are pharmaceutical compositions comprising Plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range Plasmodium and analogues of ?-galactosylceramide (?-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: May 9, 2017
    Assignees: Sanaria Inc., The Rockefeller University
    Inventors: Sumana Chakravarty, Stephen L. Hoffman, Moriya Tsuji
  • Patent number: 9610319
    Abstract: A method of treating liver cancer using a peptide based on venom from a terebrid snail, terebrid variegata, is described. The venom has a general formula of TRX3CCGCYWNGSKDVCSQSCC (SEQ ID NO: 1) and variants thereof are described.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 4, 2017
    Assignees: Research Foundation of the City University of New York, The Rockefeller University
    Inventors: Mande Holford, Prachi Anand, Beatrix Ueberheide, Brian Chait
  • Patent number: 9597320
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 21, 2017
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Patent number: 9587025
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: March 7, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 9532980
    Abstract: The invention provides methods for treating A? peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: January 3, 2017
    Assignee: The Rockefeller University
    Inventors: Marc Flajolet, Paul Greengard
  • Publication number: 20160376371
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicants: The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • Publication number: 20160331726
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 17, 2016
    Applicant: The Rockefeller University
    Inventors: Sohail F. Tavazoie, Nora Pencheva
  • Patent number: 9492414
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: November 15, 2016
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Jia M. Loo
  • Patent number: 9493841
    Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: November 15, 2016
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Kim Png
  • Publication number: 20160319006
    Abstract: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human ?-amyloid peptide as compare to low molecular weight forms of ?-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of ?-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 3, 2016
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Hidehiro Fukuyama
  • Patent number: 9481724
    Abstract: Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: November 1, 2016
    Assignees: The Rockefeller University, Sloan-Kettering Institute for Cancer Research
    Inventors: Jeffrey Ravetch, Andrew Pincetic, Ping Wang, Sam Danishefsky
  • Patent number: 9476048
    Abstract: The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 25, 2016
    Assignee: The Rockefeller University
    Inventors: Sebastien Pfeffer, Thomas Tuschl
  • Patent number: 9475834
    Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2—R5 and R10—R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: October 25, 2016
    Assignee: The Rockefeller University
    Inventors: Sean Brady, Hahk-Soo Kang
  • Patent number: 9447454
    Abstract: The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 20, 2016
    Assignee: The Rockefeller University
    Inventors: Robert Darnell, Kirk Jensen, Jernej Ule
  • Patent number: 9404922
    Abstract: The present disclosure provides recombinant phages, a Wip1 p23 receptor binding protein and a Wip1 p24 receptor binding protein that bind to Bacillus anthracis. The disclosure further provides methods and uses thereof.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: August 2, 2016
    Assignee: The Rockefeller University
    Inventors: Vincent Fischetti, Raymond Schuch, Sherry Kan
  • Patent number: 9399028
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: July 26, 2016
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nora Pencheva
  • Patent number: 9388213
    Abstract: The present invention relates to Polycomb Repressive Complex 2 (PRC2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyltransferase activity.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: July 12, 2016
    Assignee: The Rockefeller University
    Inventors: C. David Allis, Peter Lewis